Mark Levis, MD, PhD from The Johns Hopkins University, Baltimore, MD spoke on the lack of evolution in acute myeloid leukemia (AML) at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Dr Levis noted that there has not been any major new advances in 40 years. However this may be changing as a Dr Levis then continued on to discuss the RATIFY Phase III trial of daunorubicin, cytarabine, and midostaurin in treating AML patients (NCT00651261).
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates